logo
  

RSA Insurance Agrees To GBP300 Mln Sale Of Operations In Baltics, Poland

RSA Insurance Group Plc. (RSANY.PK,RSA.L,RSA) Thursday said it reached an agreement to sell each of Lietuvos Draudimas AB (Lithuania), AAS Balta (Latvia), the business of the Estonian branch of Codan Forsikring A/S, and Link4 Towarzystwo Ubezpieczen Spolka Akcyjna (Poland) to Powszechny Zaklad Ubezpieczen sa.

Assuming the completion of all four transactions, RSA will receive total aggregate consideration of around 360 million euros payable in cash.

The transactions are expected to add around 200 million pounds to the group's tangible net assets, improving its capital strength. Each transaction is expected to complete during the second half of 2014.

Stephen Hester, RSA Group Chief Executive, said, ''These disposals are in line with our stated aim of focusing the Group's geographical spread onto its core businesses in the UK & Ireland, Scandinavia, Canada and Latin America, and represent a good deal for our shareholders, customers and employees.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT